Introduction: Tumor growth rate (TGR), percentage of change in tumor volume/month, has been previously identified as an early radiological biomarker for treatment monitoring in neuroendocrine tumors (NETs) patients. We assessed the performance and reproducibility of TGR 3 months (TGR3m) as a predictor factor of progression-free survival (PFS), including the impact of imaging method and reader variability. Methods: Baseline and 3-months (±1month) CT/MRI images from patients with advanced, grade 1-2 NETs were retrospectively reviewed by 2 readers. Influence of number of targets, tumor burden and location of lesion on the performance of TGR3m to predict PFS was assessed by uni/multivariable Cox regression analysis. Agreement between readers was assessed by the Lin’s concordance coefficient (LCC) and Kappa (KC). Results: A total of 790 lesions were measured in 222 patients. Median PFS was 22.9 months. On univariable analysis, number of lesions (

中文翻译：

---

预测神经内分泌肿瘤患者预后的肿瘤生长率：表现和变异性来源。

简介：肿瘤生长率 (TGR)，即肿瘤体积/月变化的百分比，之前已被确定为神经内分泌肿瘤 (NET) 患者治疗监测的早期放射生物标志物。我们评估了 TGR 3 个月 (TGR3m) 作为无进展生存期 (PFS) 的预测因素的性能和可重复性，包括成像方法和读者变异性的影响。方法：由 2 位读者回顾性回顾了晚期 1-2 级 NET 患者的基线和 3 个月（±1 个月）CT/MRI 图像。通过单变量/多变量 Cox 回归分析评估靶点数量、肿瘤负荷和病变位置对 TGR3m 预测 PFS 性能的影响。读者之间的一致性通过 Lin 的一致性系数 (LCC) 和 Kappa (KC) 进行评估。结果：共测量了 222 名患者的 790 个病灶。中位 PFS 为 22.9 个月。在单变量分析中，病灶数 (